Core Insights - Yunding Xinyao announced the successful enrollment of the first patient in its global multicenter Phase I clinical trial for the universal off-the-shelf cancer therapeutic vaccine EVM14 at NEXT Oncology Virginia in the United States [1] Group 1: Product Overview - EVM14 is a universal off-the-shelf cancer therapeutic vaccine targeting five tumor-associated antigens (TAA) [1] - The vaccine is intended for the treatment of various squamous cell carcinomas, including non-small cell lung squamous carcinoma (sq-NSCLC) and head and neck squamous cell carcinoma (HNSCC) [1]